First-in-human clinical trial testing CRISPR/Cas9 gene-editing in 12 highly metastatic, end-stage GI cancer patients saw several of their cancer growth halt & not return over 2 year period.
First-in-human clinical trial testing CRISPR/Cas9 gene-editing in 12 highly metastatic, end-stage GI cancer patients saw several of their cancer growth halt & not return over 2 year period.
med.umn.edu
New gene-editing therapy shows early success in fighting advanced GI cancers